Cost-Effectiveness of Conjugate Meningococcal Vaccination Strategies in the United States

Authors:
  • TTthe ABCs Team
    the ABCs Team

Abstract
Context. The US Food and Drug Administration approved a meningococcal conjugate A/C/Y/W-135 vaccine (MCV-4) for use in persons aged 11 to 55 years in January, 2005; licensure for use in younger age groups is expected in 2 to 4 years.

This publication has 51 references indexed in Scilit: